This is a renewal R01 application to exploit previously generated mouse models of germline-reverted HIV Env broadly neutralizing antibodies (gl-bNAbs) and to generate new ones. Developing an effective HIV vaccine is an important goal, as it would facilitate the major public health objective of HIV prevention. The recent identification of bNAbs to HIV Env has shown that such responses are possible. Moreover, animal challenge studies after passive immunization have shown that these bNAbs can be protective. Structural studies have identified the key epitopes at the molecular level, aiding vaccine design. Small animal models potentially can aid HIV vaccine development by allowing one to rapidly assess vaccine candidates and to determine the roadblocks to appropriate gl-bNAb B cell activation and maturation. The hypothesis of this proposal is that mice and B cell lines expressing gl-bNAbs can be useful tools in defining how best to initially stimulate, and then later to train, B cells to generate the desird bNAb responses. Because the problem of poor precursor affinity to antigen is a limitation to all immune responses, knowledge obtained here should be applicable to a variety of vaccine targets. We address these goals through the following Specific Aims: 1) To elicit bNAbs from exisiting gl-bNAb targeted (knock-in) B cells using designer immunogens. Antigens that target naive gl-b12 and gl-4E10 B cells will be used in immunization studies to characterize how best to generate high affinity bNAbs. These studies will be facilitated by the availability of our recently generated germline b12 and 4E10 knock-in mice and specially designed ligands directed to these gl-bNAbs. 2) To generate new gl-bNAb knock-ins for VRC01, 10E8, and either PGT121 or PG9. bNAbs VRC01, 10E8, PG9 and PGT121 see independent, conserved Env epitopes. These potent bNAbs currently appear to be better models than b12 and 4E10 for the development of a good HIV vaccine. Genes for VRC01, 10E8, and either PGT121 or PG9 will be used in the generation of gl-bNAb knock-in mice and in the testing of epitope-scaffold immunogens. These knock-in gl-bNAb mice will be ideal for working out the best ligands and methods for testing in human immunization.

Public Health Relevance

A successful HIV vaccine needs to elicit antibodies that neutralize many strains of the virus. To understand how such antibodies can be elicited by vaccination, we propose to study existing and new mouse models carrying genes encoding low affinity, non mutated anti-HIV antibodies, generated by reverting affinity enhancing mutations of broadly neutralizing antibodies. These so called knock-in mice will be used in vaccine immunization studies to assess their utility in testing and ranking vaccine candidates for their ability to stimulate antibodies that attain high affinity and broad reactivity to different HIV strins.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
HIV/AIDS Vaccines Study Study Section (VACC)
Program Officer
Malaspina, Angela
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
Research Institutes
La Jolla
United States
Zip Code
Nemazee, David (2017) Mechanisms of central tolerance for B cells. Nat Rev Immunol 17:281-294
Medina-Ramírez, Max; Garces, Fernando; Escolano, Amelia et al. (2017) Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med 214:2573-2590
Ingale, Jidnyasa; Stano, Armando; Guenaga, Javier et al. (2016) High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep 15:1986-99
Briney, Bryan; Sok, Devin; Jardine, Joseph G et al. (2016) Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell 166:1459-1470.e11
He, Linling; de Val, Natalia; Morris, Charles D et al. (2016) Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun 7:12041
Jardine, Joseph G; Ota, Takayuki; Sok, Devin et al. (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349:156-61
Jardine, Joseph; Julien, Jean-Philippe; Menis, Sergey et al. (2013) Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-6
Doores, Katie J; Huber, Michael; Le, Khoa M et al. (2013) 2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies. J Virol 87:2234-41
Ota, Takayuki; Doyle-Cooper, Colleen; Cooper, Anthony B et al. (2013) B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. J Immunol 191:3179-85
Doyle-Cooper, Colleen; Hudson, Krystalyn E; Cooper, Anthony B et al. (2013) Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J Immunol 191:3186-3191

Showing the most recent 10 out of 12 publications